Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$13.75
+1.70%
HEALTHCARE · Cap: $5.17B
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.71%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 470% more annual revenue ($17.35B vs $3.05B). TEVA leads profitability with a 9.0% profit margin vs 4.0%. TEVA trades at a lower P/E of 25.8x. TEVA earns a higher WallStSmart Score of 66/100 (B-).
AMRX
Hold44
out of 100
Grade: D
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.1%
Fair Value
$22.32
Current Price
$13.75
$8.57 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 384.6% YoY
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
3.9% revenue growth
4.0% margin — thin
Premium valuation, high expectations priced in
ROE of -881.0% — below average capital efficiency
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth, Debt/Equity.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are Revenue Growth, Profit Margin, P/E Ratio. A P/E of 43.8x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMRX carries more volatility with a beta of 1.32 — expect wider price swings.
AMRX is growing revenue faster at 3.9% — sustainability is the question.
AMRX generates stronger free cash flow (-43M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (66/100 vs 44/100). AMRX offers better value entry with a 34.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?